CN101011428A - Traditional Chinese medicine for treating muscle atrophy, myositis, myasthenia gravis and myodystrophia - Google Patents
Traditional Chinese medicine for treating muscle atrophy, myositis, myasthenia gravis and myodystrophia Download PDFInfo
- Publication number
- CN101011428A CN101011428A CN 200710079011 CN200710079011A CN101011428A CN 101011428 A CN101011428 A CN 101011428A CN 200710079011 CN200710079011 CN 200710079011 CN 200710079011 A CN200710079011 A CN 200710079011A CN 101011428 A CN101011428 A CN 101011428A
- Authority
- CN
- China
- Prior art keywords
- myositis
- chinese medicine
- myasthenia gravis
- capense
- phellinus igniarius
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 18
- 201000002481 Myositis Diseases 0.000 title claims abstract description 12
- 206010028417 myasthenia gravis Diseases 0.000 title claims abstract description 12
- 206010028289 Muscle atrophy Diseases 0.000 title 1
- 230000020763 muscle atrophy Effects 0.000 title 1
- 201000000585 muscular atrophy Diseases 0.000 title 1
- 241000123113 Phellinus igniarius Species 0.000 claims abstract description 16
- 206010002027 Amyotrophy Diseases 0.000 claims abstract description 11
- 201000006938 muscular dystrophy Diseases 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 3
- 241001149422 Ganoderma applanatum Species 0.000 claims description 13
- 241000222336 Ganoderma Species 0.000 abstract 2
- 241001489100 Ganoderma capense Species 0.000 abstract 2
- 239000000470 constituent Substances 0.000 abstract 1
- 235000008216 herbs Nutrition 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000012567 medical material Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- BIXJFIJYBLJTMK-UHFFFAOYSA-N Lysergol Natural products C1=CC(C2=CC(CO)CN(C2C2)C)=C3C2=CNC3=C1 BIXJFIJYBLJTMK-UHFFFAOYSA-N 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- BIXJFIJYBLJTMK-MEBBXXQBSA-N lysergol Chemical compound C1=CC(C2=C[C@@H](CO)CN([C@@H]2C2)C)=C3C2=CNC3=C1 BIXJFIJYBLJTMK-MEBBXXQBSA-N 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to a Chinese medicament for treating amyotrophy, myositis, myasthenia gravis and muscular dystrophy. The medicament comprises the following raw material medicinal herbs (by weight portion): Ganoderma capense (Lloyd) Teng 5-120, Phellinus igniarius 5-115, Ganoderma apparatus 5-125, the preferred weight ratio of the constituents includes Ganoderma capense (Lloyd) Teng 20, Phellinus igniarius 15, Ganoderma apparatus 25.
Description
Technical field
The present invention relates to a kind of Chinese medicine for the treatment of amyotrophy, myositis, myasthenia gravis, muscular dystrophy.
Background technology
At present, state's internal therapy amyotrophy, myositis, myasthenia gravis, the medicine of muscular dystrophy aspect is a lot, but in Chinese medicine, the Chinese medicine that the treatment works well seldom can not reach the therapeutic effect that treatment combines with functional rehabilitation.The invention provides a kind of treatment amyotrophy, myositis, myasthenia gravis, the reasonable medicine in muscular dystrophy aspect.
Summary of the invention
The purpose of this invention is to provide a kind of Chinese medicine for the treatment of amyotrophy, myositis, myasthenia gravis, muscular dystrophy, and easy to use, can reach the therapeutic effect that treatment combines with functional rehabilitation.
The present invention is made up of three kinds of medicines, that is: Ganaderma capense, Phellinus igniarius (L. ex Fr.) Quel., Ganoderma applanatum (Pers. Ex Wallr) Pat..
Ganaderma capense: warm in nature, sweet in the mouth, little suffering, vital essence replenishing and marrow benifiting, guarantor's lung, kidney tonifying, hemostasis dysentery, end consumptive disease and cough.Contain abundant organic selenium and other trace elements and polysaccharide, the Chinese Academy of Medical Sciences once was used for the treatment of lupus erythematosus, scleroderma, had obtained better curative effect.
Phellinus igniarius (L. ex Fr.) Quel.: sweet, suffering, flat, nontoxic.The energy heat-clearing and toxic substances removing, astringing to arrest bleeding, sharp the five internal organs, a surname's intestinal gas.Be applicable to bleeding not during menses, stranguria with blood, proctoptosis, discharging fresh blood stool, rich's strain etc.The Phellinus igniarius (L. ex Fr.) Quel. sporophore has good antitumaous effect, contains agaric acid, lysergol etc., and the hot water extract is 96.7% to the suppression ratio of white mice sarcoma S-180, is 87% to the suppression ratio of white mice ehrlich carcinoma.
Ganoderma applanatum (Pers. Ex Wallr) Pat.: little hardship, flat.The energy expelling wind and removing dampness, clearing away heat to alleviate pain, hemostasis and phlegm, promoting digestion and removing stagnation, anticancer.Be used for the treatment of acute chronic hepatitis, esophageal carcinoma, cancer of pancreas, digestive tract ulcer, early stage liver cirrhosis among the people more, also can be used for treating hemorrhoidal hamorrhage and rush down blood, heat long-pending chest and diaphragm, neurasthenia, dyspepsia, rheumatic pulmonary tuberculosis and the nourishing and fit keeping function effect is arranged.
The cooperation of three kinds of Chinese medicine medical materials can reach and hold up, prevents, controls three bonded advantages, is to form according to traditional Chinese medical science monarch, minister, the principle phase proportioning helping, make, and amyotrophy, myositis, myasthenia gravis, muscular dystrophy are had curative effect preferably.Three months is a course of treatment, can serve on 3-4 the course of treatment.
The object of the present invention is achieved like this:
Contain Ganaderma capense in the Chinese medicine of treatment amyotrophy of the present invention, myositis, myasthenia gravis, muscular dystrophy, Phellinus igniarius (L. ex Fr.) Quel., Ganoderma applanatum (Pers. Ex Wallr) Pat..
The weight proportion of described this Chinese medicine medicinal raw material consists of Ganaderma capense 5-120, Phellinus igniarius (L. ex Fr.) Quel. 5-115, Ganoderma applanatum (Pers. Ex Wallr) Pat. 5-125.
The optimum weight proportioning of described each component is a Ganaderma capense 20, Phellinus igniarius (L. ex Fr.) Quel. 15, Ganoderma applanatum (Pers. Ex Wallr) Pat. 25.
The present invention is by the Chinese crude drug Ganaderma capense, and Phellinus igniarius (L. ex Fr.) Quel., Ganoderma applanatum (Pers. Ex Wallr) Pat. are formed, Ganaderma capense 5-120g wherein, and Phellinus igniarius (L. ex Fr.) Quel. 5-115g, Ganoderma applanatum (Pers. Ex Wallr) Pat. 5-125g, this is a potion, is a staggering amount.
During use, in marmite, put into 500g water, three kinds of medical materials are put into pot by a dosage, fry in shallow oil about 150g water, day clothes 1 time.
The invention has the beneficial effects as follows: prescription of the present invention is simple, and treatment amyotrophy, myositis, myasthenia gravis, muscular dystrophy are had tangible effect.
The specific embodiment
Get Ganaderma capense 120g, Phellinus igniarius (L. ex Fr.) Quel. 115g, Ganoderma applanatum (Pers. Ex Wallr) Pat. 125g puts into 500g water in marmite, three kinds of medical materials are put into pot, fries in shallow oil about 150g water and obeys 1 time day.
Get Ganaderma capense 100g, Phellinus igniarius (L. ex Fr.) Quel. 95g, Ganoderma applanatum (Pers. Ex Wallr) Pat. 105g puts into 500g water in marmite, three kinds of medical materials are put into pot, fries in shallow oil about 150g water and obeys 1 time day.
Get Ganaderma capense 75g, Phellinus igniarius (L. ex Fr.) Quel. 70g, Ganoderma applanatum (Pers. Ex Wallr) Pat. 90g puts into 500g water in marmite, three kinds of medical materials are put into pot, fries in shallow oil about 150g water and obeys 1 time day.
Get Ganaderma capense 60g, Phellinus igniarius (L. ex Fr.) Quel. 55g, Ganoderma applanatum (Pers. Ex Wallr) Pat. 75g puts into 500g water in marmite, three kinds of medical materials are put into pot, fries in shallow oil about 150g water and obeys 1 time day.
Claims (2)
1, a kind of Chinese medicine for the treatment of amyotrophy, myositis, myasthenia gravis, muscular dystrophy, it is characterized in that: the weight proportion of this Chinese medicine medicinal raw material consists of Ganaderma capense 5-120, Phellinus igniarius (L. ex Fr.) Quel. 5-115, Ganoderma applanatum (Pers. Ex Wallr) Pat. 5-125.
2, the Chinese medicine of treatment amyotrophy according to claim 1, myositis, myasthenia gravis, muscular dystrophy is characterized in that: the optimum weight proportioning of each component is a Ganaderma capense 20, Phellinus igniarius (L. ex Fr.) Quel. 15, Ganoderma applanatum (Pers. Ex Wallr) Pat. 25.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200710079011 CN101011428A (en) | 2007-02-08 | 2007-02-08 | Traditional Chinese medicine for treating muscle atrophy, myositis, myasthenia gravis and myodystrophia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200710079011 CN101011428A (en) | 2007-02-08 | 2007-02-08 | Traditional Chinese medicine for treating muscle atrophy, myositis, myasthenia gravis and myodystrophia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101011428A true CN101011428A (en) | 2007-08-08 |
Family
ID=38699263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200710079011 Pending CN101011428A (en) | 2007-02-08 | 2007-02-08 | Traditional Chinese medicine for treating muscle atrophy, myositis, myasthenia gravis and myodystrophia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101011428A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105596713A (en) * | 2016-01-05 | 2016-05-25 | 蒋金霞 | Traditional Chinese medicine preparation for treating polymyositis |
| CN106265709A (en) * | 2016-09-05 | 2017-01-04 | 中国药科大学 | Catalpol is in preparation preventing and treating or delays the application in myasthenia and/or amyotrophic medicine |
| JP2020005603A (en) * | 2018-07-12 | 2020-01-16 | 日本メナード化粧品株式会社 | Athletic ability-improving agent |
| JP2022067043A (en) * | 2020-10-19 | 2022-05-02 | 葡萄王生技股▲ふん▼有限公司 | Method for improving sarcopenia |
| CN114984066A (en) * | 2021-03-01 | 2022-09-02 | 葡萄王生技股份有限公司 | Application of phellinus igniarius in preparation of composition for improving sarcopenia |
-
2007
- 2007-02-08 CN CN 200710079011 patent/CN101011428A/en active Pending
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105596713A (en) * | 2016-01-05 | 2016-05-25 | 蒋金霞 | Traditional Chinese medicine preparation for treating polymyositis |
| CN106265709A (en) * | 2016-09-05 | 2017-01-04 | 中国药科大学 | Catalpol is in preparation preventing and treating or delays the application in myasthenia and/or amyotrophic medicine |
| JP2020005603A (en) * | 2018-07-12 | 2020-01-16 | 日本メナード化粧品株式会社 | Athletic ability-improving agent |
| JP7253764B2 (en) | 2018-07-12 | 2023-04-07 | 日本メナード化粧品株式会社 | athletic performance enhancer |
| JP2022067043A (en) * | 2020-10-19 | 2022-05-02 | 葡萄王生技股▲ふん▼有限公司 | Method for improving sarcopenia |
| TWI766394B (en) * | 2020-10-19 | 2022-06-01 | 葡萄王生技股份有限公司 | Use of phellinus linteus for preparing composition of improving sarcopenia |
| JP7250065B2 (en) | 2020-10-19 | 2023-03-31 | 葡萄王生技股▲ふん▼有限公司 | Compositions for ameliorating sarcopenia |
| US11944659B2 (en) | 2020-10-19 | 2024-04-02 | Grape King Bio Ltd | Method for improving sarcopenia by using Phellinus linteus |
| CN114984066A (en) * | 2021-03-01 | 2022-09-02 | 葡萄王生技股份有限公司 | Application of phellinus igniarius in preparation of composition for improving sarcopenia |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101011428A (en) | Traditional Chinese medicine for treating muscle atrophy, myositis, myasthenia gravis and myodystrophia | |
| CN101485450A (en) | Health food containing Cordyceps sinensis and glossy ganoderma spore powder | |
| CN105582428A (en) | Transdermal patch for acupoint sticking therapy and preparation method thereof | |
| CN1583001A (en) | Infrared cough relieving paste | |
| CN102872368B (en) | Chinese medicine acupoint application preparation for purging fire for removing toxin | |
| CN106692822A (en) | Traditional Chinese medicine pills for treating tracheobronchitis | |
| CN101011429A (en) | Traditional Chinese medicine for treating uremia | |
| CN101011425A (en) | Traditional Chinese medicine for treating esophagus cancer, gastric cancer, uterocarcinoma and hysteromyoma | |
| CN102406861B (en) | External medicament for treating bronchitis | |
| CN1237998C (en) | Effervescence tablet for treating children's cough and asthma and its preparation | |
| CN110882372B (en) | Navel patch for treating infantile diarrhea | |
| CN108159218A (en) | A kind of preparation method of two old extracts and its preparation with antitumor activity | |
| CN101028297A (en) | Chinese medicine for treating hepatic hepatic hydroperitonia | |
| CN100508998C (en) | Weibingkang for treating stomach disease | |
| CN106729097A (en) | A kind of Chinese medicine composition for treating wind-warm lung-heat | |
| CN101028296A (en) | Chinese medicine for treating tumor | |
| CN101011427A (en) | Chinese traditional medicine for treating Cazenave's lupus and sclerodermas | |
| CN104474292A (en) | Pharmaceutical composition for preventing and treating influenza and preparation method of pharmaceutical composition | |
| CN104721295A (en) | Chinese and western medicine composition for treating various kinds of wind fire toothache and preparation method thereof | |
| CN107007752A (en) | A kind of Chinese medicine composition for improving anoxia endurance | |
| CN101028299A (en) | Chinese medicine for treating cardiopathy | |
| CN107789542A (en) | A kind of Chinese medicine composition for treating asthma | |
| CN101028295A (en) | Chinese medicine for treating hepatitis B | |
| CN104127530A (en) | Decoction for treating colitis | |
| CN104043074A (en) | Traditional Chinese medicine preparation for treating enduring cough for many years |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Beijing Tian Zhi Shen wild Ganoderma lucidum science and Technology Research Institute Assignor: Chen Kanglin Contract fulfillment period: 2007.11.6 to 2024.12.10 contract change Contract record no.: 2007990000093 Denomination of invention: Traditional Chinese medicine for treating muscle atrophy, myositis, myasthenia gravis and myodystrophia Granted publication date: Wei Shouquan License type: Exclusive license, sub license Record date: 2007.12.3 |
|
| LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENCE; TIME LIMIT OF IMPLEMENTING CONTACT: 2007.11.6 TO 2024.12.10 Name of requester: BEIJING TIAN-ZHI HUASHEN WILD GANODERMA LUCIDUM S Effective date: 20071203 |
|
| ASS | Succession or assignment of patent right |
Owner name: SHI HAIYAN Free format text: FORMER OWNER: CHEN KANGLIN Effective date: 20080718 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20080718 Address after: Room 717, B block, 27 international capital center, South Binhe Road, Beijing, Xuanwu District, China: 100055 Applicant after: Shi Haiyan Address before: 7, Liyuan villa, South long Kun Road, Hainan, Haikou Province, China: 570000 Applicant before: Chen Kanglin |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |